Understanding the role of MS4A3 in blood cell development and leukemia
Official title: The function of MS4A3 in normal and malignant hematopoiesis
Funded at Versiti Wisconsin, INC. · NIH-11003363 · Data updated 2026-11-12
This study is looking at how a protein called MS4A3 influences blood cell development and the progression of chronic myeloid leukemia, especially for patients whose leukemia doesn't respond to regular treatments, with the hope of finding new ways to help improve their care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Versiti Wisconsin, INC. NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | January 1, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $425,749 |
| NIH project number | 5R01CA268496-03 |
| Project ID | NIH-11003363 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with chronic myeloid leukemia, particularly those experiencing resistance to standard therapies.
✕Less likely to help
Patients with other types of leukemia or those who are not diagnosed with chronic myeloid leukemia may not benefit from this research.
What this research studies
This research investigates how the MS4A3 protein affects the development of blood cells and the progression of chronic myeloid leukemia (CML). It focuses on the challenges faced by patients whose leukemia does not respond to standard treatments, particularly those with a form of the disease that is resistant to therapy. By studying the relationship between MS4A3 expression and leukemia cell behavior, the research aims to uncover new therapeutic targets that could improve patient outcomes. The approach includes analyzing blood samples and conducting experiments to manipulate MS4A3 levels in leukemia cells.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively target resistant leukemia cells, potentially improving survival rates for patients with CML.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways in leukemia, indicating that this approach could yield significant advancements.
Where this research is happening
-
Versiti Wisconsin, INC.
Milwaukee, United States Active
Researchers
- Principal investigator: Deininger, Michael W. — Versiti Wisconsin, INC.
- Study coordinator: Deininger, Michael W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.